Oncopeptides AB (publ) (ONCO.ST)
SEK 1.54
(1.18%)
SEK 1.54
(1.18%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 35.22 Million SEK | 321.54% |
| 2022 | 8.35 Million SEK | -92.94% |
| 2021 | 118.29 Million SEK | 0.0% |
| 2020 | - SEK | 0.0% |
| 2019 | - SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 5.07 Million SEK | -4.97% |
| 2024 Q2 | 8.15 Million SEK | 60.78% |
| 2023 Q2 | 25.95 Million SEK | 2209.07% |
| 2023 FY | 35.22 Million SEK | 321.54% |
| 2023 Q4 | 5.33 Million SEK | 90.27% |
| 2023 Q3 | 2.8 Million SEK | -89.19% |
| 2023 Q1 | 1.12 Million SEK | 100.71% |
| 2022 Q1 | - SEK | 100.0% |
| 2022 FY | 8.35 Million SEK | -92.94% |
| 2022 Q2 | 8.75 Million SEK | 0.0% |
| 2022 Q4 | 560 Thousand SEK | 158.46% |
| 2022 Q3 | -958 Thousand SEK | -110.94% |
| 2021 Q2 | 66.37 Million SEK | 242.93% |
| 2021 Q1 | 19.35 Million SEK | 0.0% |
| 2021 FY | 118.29 Million SEK | 0.0% |
| 2021 Q3 | 54.27 Million SEK | -18.23% |
| 2021 Q4 | -21.71 Million SEK | -140.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 39.388% |
| Ziccum AB (publ) | 3.74 Million SEK | -839.952% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 94.282% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 30.237% |
| Mendus AB (publ) | 28.48 Million SEK | -23.635% |
| Genovis AB (publ.) | 158.23 Million SEK | 77.742% |
| Intervacc AB (publ) | 8.01 Million SEK | -339.426% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -705.213% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 79.336% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 19.765% |
| Aptahem AB (publ) | 2.63 Million SEK | -1238.834% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -3302.899% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -45640.26% |
| Fluicell AB (publ) | 3.33 Million SEK | -955.123% |
| Saniona AB (publ) | 16.84 Million SEK | -109.145% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -114.664% |
| Biovica International AB (publ) | 7.29 Million SEK | -383.128% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -2827.681% |
| AcouSort AB (publ) | 10.55 Million SEK | -233.807% |
| Xintela AB (publ) | 78 Thousand SEK | -45053.846% |
| Abliva AB (publ) | 137 Thousand SEK | -25608.029% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 38.854% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -1648.759% |
| OncoZenge AB (publ) | 3000.00 SEK | -1173900.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -22622.581% |
| CombiGene AB (publ) | 5.54 Million SEK | -535.268% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 97.082% |
| Camurus AB (publ) | 1.71 Billion SEK | 97.949% |
| Corline Biomedical AB | 25.03 Million SEK | -40.711% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -520.289% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -4784.882% |
| I-Tech AB | 120.86 Million SEK | 70.859% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 73.735% |
| Cyxone AB (publ) | 5.14 Million SEK | -584.149% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -399.574% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -230.248% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -213.622% |
| Nanologica AB (publ) | 1.44 Million SEK | -2340.748% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -66352.83% |
| BioInvent International AB (publ) | 71.46 Million SEK | 50.714% |
| Alzinova AB (publ) | 270 Thousand SEK | -12944.444% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -2307.349% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -1148.051% |
| Simris Alg AB (publ) | 4.35 Million SEK | -708.911% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -26992.308% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 85.247% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -153030.435% |